Medpace (NASDAQ:MEDP) Price Target Raised to $673.00

Medpace (NASDAQ:MEDP) had its target price upped by TD Cowen from $492.00 to $673.00 in a research report report published on Friday morning, MarketBeat reports. They currently have a hold rating on the stock.

A number of other research analysts also recently weighed in on MEDP. Royal Bank Of Canada raised their target price on shares of Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. Mizuho boosted their price target on shares of Medpace from $665.00 to $700.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 7th. Jefferies Financial Group reissued a “hold” rating on shares of Medpace in a research report on Monday, September 14th. Barclays increased their price objective on shares of Medpace from $625.00 to $675.00 and gave the stock an “equal weight” rating in a research note on Friday. Finally, Leerink Partners set a $620.00 price objective on Medpace in a report on Thursday, July 23rd. Three investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $642.91.

Medpace Price Performance

NASDAQ:MEDP opened at $669.20 on Friday. The company has a market cap of $18.72 billion, a P/E ratio of 37.10, a price-to-earnings-growth ratio of 2.90 and a beta of 1.18. Medpace has a twelve month low of $373.00 and a twelve month high of $684.52. The business has a 50 day moving average price of $611.66 and a two-hundred day moving average price of $537.96.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Wednesday, October 21st. The company reported $4.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.44 by $0.40. Medpace had a net margin of 18.24% and a return on equity of 99.76%. The company had revenue of $716.00 million for the quarter, compared to the consensus estimate of $714.47 million. During the same period last year, the company earned $3.86 earnings per share. The firm’s revenue was up 8.5% compared to the same quarter last year. As a group, analysts anticipate that Medpace will post 18.06 earnings per share for the current fiscal year.

Insider Buying and Selling at Medpace

In other news, CEO August Troendle sold 49,018 shares of the company’s stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $628.11, for a total transaction of $30,788,695.98. Following the sale, the chief executive officer owned 433,372 shares in the company, valued at $272,205,286.92. This represents a 10.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Over the last quarter, insiders sold 332,412 shares of company stock worth $205,768,359. 20.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Medpace

A number of institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in Medpace in the second quarter valued at $1,323,047,000. Wasatch Advisors LP increased its stake in shares of Medpace by 19.4% during the 1st quarter. Wasatch Advisors LP now owns 773,931 shares of the company’s stock worth $371,634,000 after purchasing an additional 125,625 shares during the last quarter. State Street Corp increased its stake in shares of Medpace by 4.2% during the 2nd quarter. State Street Corp now owns 710,895 shares of the company’s stock worth $376,483,000 after purchasing an additional 28,666 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of Medpace by 8.3% in the 1st quarter. Renaissance Technologies LLC now owns 504,668 shares of the company’s stock valued at $242,337,000 after purchasing an additional 38,760 shares during the period. Finally, Arrowstreet Capital Limited Partnership raised its holdings in shares of Medpace by 5.5% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 395,769 shares of the company’s stock valued at $190,044,000 after purchasing an additional 20,736 shares during the period. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Key Medpace News

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: New $1 billion buyback: Medpace authorized a $1 billion repurchase program, replacing its previous authorization. The plan signals management’s confidence in cash generation and could support earnings per share by reducing the share count. Medpace Announces $1 Billion Stock Buyback Program
• Positive Sentiment: Raised 2026 outlook: The company forecast adjusted EPS of $17.97–$18.32, above the $17.68 analyst consensus, while revenue guidance of $2.8–$2.9 billion is broadly consistent with expectations. Medpace 2026 Guidance and Buyback
• Positive Sentiment: Q3 earnings beat: Medpace reported earnings of $4.84 per share versus the $4.45 consensus estimate, with revenue of approximately $716 million and year-over-year revenue growth of 8.5%. Margin expansion helped drive the earnings outperformance. Medpace Q3 Earnings Beat
• Positive Sentiment: Demand remains healthy: Net new business awards reached $873 million in the third quarter, and ending backlog increased 5.6% year over year to $3.2 billion, supporting future revenue visibility. Medpace Long-Term Investor Takeaways
• Neutral Sentiment: Analyst targets moved higher but ratings remain cautious: TD Cowen raised its target to $673 from $492 and kept a “hold” rating, while Deutsche Bank increased its target to $650 and also maintained “hold.” These revisions acknowledge the improved outlook but imply limited upside at recent trading levels. TD Cowen Medpace Rating
• Negative Sentiment: Valuation remains a concern: Commentary following the results questioned whether MEDP is already pricing in much of its growth, with some analysis describing the shares as materially overvalued despite the earnings beat. This may explain the initial post-earnings hesitation.

About Medpace

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the development process, from early-stage planning and regulatory submissions through clinical trial execution, data management, analysis and reporting.

Medpace’s services include Phase I through Phase IV clinical research, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.